Drug Trial Radar · NCT02154490
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jun 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,864
Actual
Start
Jul 8, 2014
Primary completion
Apr 1, 2022
Study completion Apr 15, 2022
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 3, 2014
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a ?non-match? sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.
Conditions
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
DocetaxelDrug
Given IV
DurvalumabBiological
Given IV
Erlotinib HydrochlorideDrug
Given PO
FGFR Inhibitor AZD4547Drug
Given PO
IpilimumabBiological
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
NivolumabBiological
Given IV
PalbociclibDrug
Given PO
Pharmacological StudyOther
Correlative studies
RilotumumabBiological
Given IV
TalazoparibDrug
Given PO
TaselisibDrug
Given PO
TremelimumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Screen Success RateTime frame: From date of registration to pre-screening or screening component until sub-study registration or death, a median of 3.5 months (IQR 2.0-6.0) in the pre-screened group and 0.9 months (IQR 0.7-1.1) in the screened at progression group.
Locations
1,004 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Regional Hospital
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
University of Arizona Cancer Center-North Campus
Tucson, Arizona
The University of Arizona Medical Center-University Campus
Tucson, Arizona
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
Fowler Family Center for Cancer Care
Jonesboro, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Mills-Peninsula Medical Center
Burlingame, California
City of Hope Corona
Corona, California
City of Hope Comprehensive Cancer Center
Duarte, California
Kaiser Permanente-Fontana
Fontana, California
Kaiser Permanente-Fremont
Fremont, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Washington Hospital
Fremont, California
Kaiser Permanente-Fresno
Fresno, California
Saint Jude Medical Center
Fullerton, California
Kaiser Permanente - Harbor City
Harbor City, California
Kaiser Permanente-Irvine
Irvine, California
UC San Diego Moores Cancer Center
La Jolla, California
City of Hope Antelope Valley
Lancaster, California
Loma Linda University Medical Center
Loma Linda, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Los Angeles County-USC Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Kaiser Permanente-Cadillac
Los Angeles, California
Showing 40 of 1,004 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.